Add Yahoo as a preferred source to see more of our stories on Google. Lynk Pharmaceuticals' next generation JAK inhibitor Lynk Pharmaceuticals has posted positive topline results from a Phase III ...
Lynk Pharmaceuticals has posted positive topline results from a Phase III trial on its next generation Janus kinase 1 (JAK1) inhibitor, zemprocitinib, in rheumatoid arthritis (RA). During the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results